St. John’s Wort for Vitiligo: A Simple, Low-Cost Way to Partially Ease the Problem
St. John’s wort has long been used in phytomedicine as a natural antidepressant, antispasmodic, and diuretic—and also as a photosensitizer. […]
phototherapy
How to Sleep to Slow Facial Aging: Posture, Pillows, and Night Routine
Key Takeaways Back-sleeping (supine) minimizes mechanical sleep creases and morning puffiness. Side-sleeping is acceptable with the right pillow height (≈12–15 cm)
NB-UVB 311 nm in Vitiligo: Dosing Protocols, Cohort Outcomes, and Practical Tips
Key Takeaways Backbone therapy for generalized/nonsegmental vitiligo; best responses on face/neck, slower on acral sites. Start low, escalate by 10–20%
Segmental vs Nonsegmental Vitiligo: Clinical Patterns, Prognosis, and Treatment Strategy
Key Takeaways Segmental vitiligo (SV): unilateral/dermatomal clusters, rapid early spread then stability, frequent leukotrichia, limited systemic autoimmunity, best long-term results
NB-UVB 311 nm in Nonsegmental Vitiligo: Cohort Outcomes, Protocols, and Site-Specific Response
Key Takeaways Backbone therapy for generalized/nonsegmental vitiligo; best outcomes on face/neck, slower on acral sites. Typical schedule 2–3×/week for 24–48
NB-UVB 311 nm in Nonsegmental Vitiligo: Cohort Outcomes, Protocols, and Safety (n≈150–200)
Key Takeaways Backbone therapy for generalized/nonsegmental vitiligo with best responses on face/neck; acral lesions remain hardest. Typical schedules: 2–3×/week, incremental
Autoimmunity in Vitiligo: IFN-γ–CXCL9/10 Axis and Tissue-Resident Memory T Cells (TRM)
Key Takeaways IFN-γ induces keratinocyte/immune-cell secretion of CXCL9/10, recruiting CXCR3+ cytotoxic T cells that kill melanocytes. CD8+ TRM persist in
NB-UVB + Tacrolimus vs NB-UVB Alone in Vitiligo: Randomized Controlled Trial
Key Takeaways Adding topical tacrolimus to NB-UVB is associated with higher facial response rates and earlier perifollicular repigmentation in many
NB-UVB 311 nm for Vitiligo: Cohort Evidence, Protocols, Predictors, and Safety
Key Takeaways NB-UVB (311–313 nm) consistently induces clinically meaningful repigmentation across multiple cohorts; face responds best, acral sites worst. Typical regimens